HOME >> BIOLOGY >> NEWS
Busy weeks ahead for high-flying students

This year's Student Parabolic Flight Campaign, organised by ESA's Education Office, will see experiments performed in a variety scientific areas including physics, human biology, material science and robotics, some using objects as diverse as jelly and moths.

Fours flights in two weeks

During the fortnight four parabolic flights will take place. The Airbus A-300, operated on behalf of ESA by the French company Novespace, will take off from Bordeaux-Mrignac airport and fly out high above France's Atlantic coast. Thirty-one parabolas will be performed during each flight, with each parabola providing about 20 seconds of weightlessness. As part of a special science week in Belgium, and to promote ESA's parabolic flight campaigns within the Belgian student community, the first flight of this campaign will take off from Bordeaux and land in Brussels, a first for ESA.

The 32 teams have been divided into two groups, with half flying in the first week and half in the second week. In all over 120 students will participate in the campaign, together representing universities from 15 countries.

Being on board a parabolic flight brings all kinds of new sensations, quite unlike anything experienced on Earth. To help the students concentrate on their experiments during the main campaign flights, they will also fly on a shorter five-parabola familiarisation flight. Throughout this flight the students will be safely buckled into their seats in the front cabin area.

Jelly balls and moths

The students have already had to work hard to get to Bordeaux. After two selection rounds, the students have been working flat out on constructing their experiments since the beginning of April. On this campaign, the students are no less inventive than in previous years.

One team from Germany, will be using balls made of jelly to model planet oscillations. The other teams will be pleased to know that their experi
'"/>

Contact: Dieter Isakeit
dieter.isakeit@esa.int
31-071-565-5451
European Space Agency
16-Jul-2003


Page: 1 2

Related biology news :

1. Differences between boys and girls show less than three weeks into pregnancy
2. Researcher proves fetuses hears at 30 weeks
3. Embryos that implant in uterus late prove more likely to die in first weeks of pregnancy
4. International rice genome project progressing ahead of schedule
5. Go ahead with EMBO restart fellowship
6. Chemical engineering grad students will take notable national awards
7. APS awards more than $140,000 to minority students of physiology
8. Illustrated guidebook published for Chinese biomedical scientists and students
9. New textbook introduces students to the foundations, applications of nanotechnology
10. UK biotechnology business plan competition now open to students in the US and Canada
11. Beware cancer, insomnia and liver disease UH students are taking aim

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Busy weeks ahead for high flying students

(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 Audacity, ... activation agency and member of the Huntsworth Health Group, ... to its executive team. In her role, Gonzales will ... , “We are incredibly honored to welcome a talent ... Chief and CEO, Gaëtan Fraikin. “She is a proven ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: